GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RepliCel Life Sciences Inc (TSXV:RP) » Definitions » Forward PE Ratio

RepliCel Life Sciences (TSXV:RP) Forward PE Ratio : 0.00 (As of May. 27, 2024)


View and export this data going back to 2012. Start your Free Trial

What is RepliCel Life Sciences Forward PE Ratio?

RepliCel Life Sciences's Forward PE Ratio for today is 0.00.

RepliCel Life Sciences's PE Ratio without NRI for today is 3.93.

RepliCel Life Sciences's PE Ratio for today is 9999.00.


RepliCel Life Sciences Forward PE Ratio Historical Data

The historical data trend for RepliCel Life Sciences's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RepliCel Life Sciences Forward PE Ratio Chart

RepliCel Life Sciences Annual Data
Trend
Forward PE Ratio

RepliCel Life Sciences Quarterly Data
Forward PE Ratio

Competitive Comparison of RepliCel Life Sciences's Forward PE Ratio

For the Biotechnology subindustry, RepliCel Life Sciences's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RepliCel Life Sciences's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RepliCel Life Sciences's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where RepliCel Life Sciences's Forward PE Ratio falls into.



RepliCel Life Sciences Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


RepliCel Life Sciences  (TSXV:RP) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


RepliCel Life Sciences Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of RepliCel Life Sciences's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


RepliCel Life Sciences (TSXV:RP) Business Description

Traded in Other Exchanges
Address
570 Granville Street, Suite 900, Vancouver, BC, CAN, V6C 3P1
RepliCel Life Sciences Inc is a Canadian regenerative medicine company. It focuses on developing autologous cell therapies that treat functional cellular deficits. The company addresses various diseases such as chronic tendon injuries, androgenetic alopecia, and skin aging. Its development program of the company is based on distinct technology that utilizes cells isolated from a patient's healthy hair follicles. Also, the company develops a programmable cell injector device designed for dermal injections of cells, dermal filler products, and a variety of other products injected through the skin. The treatments delivered by the company use autologous cell therapy which is developed for the treatment of androgenetic alopecia. The revenue is generated from Licensing fees.

RepliCel Life Sciences (TSXV:RP) Headlines

From GuruFocus

RealPage Announces New Prepaid Debit Card Solution

By Business Wire Business Wire 07-13-2021

RealPage� Delivers On-Call Live Tours

By Business Wire Business Wire 03-10-2021